148 filings
Page 6 of 8
CORRESP
63mgw
15 Nov 19
Correspondence with SEC
12:00am
8-K
ud3z3
14 Nov 19
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications
5:19pm
8-K
s89zzw
14 Nov 19
Axonics® Announces Third Quarter 2019 Financial Results and Operational Update
4:05pm
CORRESP
6mc2r 63fz
14 Nov 19
Correspondence with SEC
12:00am
UPLOAD
x0n89ivi cp2
14 Nov 19
Letter from SEC
12:00am
S-3
z4jnk8ogk5syw
6 Nov 19
Shelf registration
5:23pm
8-K
bijh244q2c4e3npnsu
6 Nov 19
Axonics® Responds to Patent Action by Medtronic
12:00am
8-K
1ig i7uw5hx
9 Sep 19
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
4:16pm
8-K
yl2ykno4lmd7j7m6wk
22 Aug 19
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
kvitupnthwx1vd nj758
5 Aug 19
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
4:05pm
8-K
z4vsmo 91
12 Jul 19
Entry into a Material Definitive Agreement
5:29pm
DEFA14A
rqdp1gfogacq0
10 Jul 19
Additional proxy soliciting materials
12:00am
DEF 14A
n0c1kw k2yt0qp
9 Jul 19
Definitive proxy
5:29pm
8-K
e9i7dhx2s
11 Jun 19
Departure of Directors or Certain Officers
4:31pm
8-K
kb5surtxkq
8 May 19
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
4:05pm
10-K/A
bier5zqczdhof
30 Apr 19
Annual report (amended)
4:59pm
8-K
n5evyv
12 Apr 19
Axonics® Appoints Nancy L. Snyderman, M.D. and Jane E. Kiernan
4:22pm